GCOGenesco Inc.
- Next report
- Dec 3
- Thursday, in 21 days · time not announced yet
- EPS expected
- $0.94
- quarter ending Oct 31, 2026
- Price
- $36.74
- +0.64% today · $434M cap
Past and upcoming reports
2
| Dec 3, 2026 | Oct 31, 2026 | Time not announced yet | $0.94 | not yet | |
| Jun 3, 2026 | Apr 30, 2026 | Time not given | −$2.55 | not recorded | +1.24%2d |
Pre-earnings read
No pre-earnings read for this report
None for this company right now.
After the report
Jun 3, 2026 report
Genesco shares rally 9.5% post-Q1 2027 earnings despite unavailable EPS data
Genesco's stock surged 9.5% following Q1 2027 results with 3% revenue growth driven by Journeys' 5% comps and 21 new stores, offset by Schuh's 9% sales decline. EPS was not reported. Valuation remains attractive with forward P/E 27% below sector. Investors await June 3 earnings and guidance for growth clarity.
Reported against expected
EPS data unavailable. consensus estimate was -2.55 for Q1 2027.
Guidance
No explicit guidance disclosed. market reaction suggests positive sentiment toward growth prospects.
How the stock reacted
Shares rose 9.48% on earnings day, closing at $42.72, reflecting strong investor enthusiasm.
What changed
Stock price increased 9.5% after Q1 revenue growth of 3% despite missing EPS data.
What the price now assumes
Market is pricing optimism on Journeys' growth and attractive valuation despite profitability concerns.
What it means for the business
Maintain a constructive bias. monitor upcoming guidance and margin trends for confirmation.
The next one to three months, as we saw it then
Better case30%
Sustained revenue growth and margin improvement drive EPS above consensus, lifting shares.
Base case50%
Revenue growth continues modestly with stable margins. shares trade sideways to modestly higher.
Worse case20%
Profitability challenges persist with declining sales and weak margins, pressuring shares.
If you hold it
Hold shares unless June 3 guidance signals margin contraction or sales weakness.
If you are watching
Add if post-earnings guidance confirms margin improvement and sustained sales growth. avoid if guidance is negative or EPS misses consensus.
Scenario odds are a judgement, not measured.